Replies to post #192758 on Biotech Values

[iandy]

SGYP: I had difficulty comparing the trials. The trial sizes, patient populations, criteria, and protocols were too different.

As someone who suffers with colon disease and after reading a bunch of patient reports on Linzess,
I believe the patients, doctors, and a good number of the existing patients on Linzess are anxiously awaiting plecanatide approval. I doubt many people would choose a drug that has materially inferior tolerability and similar efficacy.

Andy